Seres Therapeutics Inc. (MCRB) has disclosed a new risk, in the Share Price & Shareholder Rights category.
Seres Therapeutics Inc. faces a significant business risk after receiving a notice from Nasdaq regarding a potential delisting due to its stock price falling below the $1.00 minimum bid requirement for an extended period. The company has until October 16, 2024, to regain compliance, failing which it may resort to transferring its listing to The Nasdaq Capital Market or implementing a reverse stock split. However, there is no guarantee these measures will resolve the issue, and non-compliance could lead to delisting, which would severely impact market liquidity and investor confidence in Seres Therapeutics Inc.
The average MCRB stock price target is $6.50, implying 767.36% upside potential.
To learn more about Seres Therapeutics Inc.’s risk factors, click here.
